Mario Alberto Accardi

Mario Alberto Accardi has extensive work experience in the biotechnology and pharmaceutical industries. Mario Alberto has held various roles in different companies over the years.

In 2013, Accardi worked as an Investment Associate at Entrepreneurs Fund Management LLP, a venture capital fund focusing on life sciences and technology.

From 2015 to 2018, they served as a Venture Partner at Fort Rock Capital, a venture capital and growth equity fund specializing in life sciences and healthcare investments.

In 2016, Accardi was a Board Observer at GNS Healthcare, a company that utilizes artificial intelligence and machine learning in healthcare analytics.

During the same year, they also served as a Board Member at vasopharm GmbH, a company focused on drug development for central nervous system disorders.

In 2018, Accardi joined Global Genomics Group as a Member of the Board of Advisors. The company utilizes precision medicine and artificial intelligence for developing drug targets and biomarkers.

In 2019, they became the CEO and Co-Founder of Inexia, a biotech company focused on developing intranasal orexin positive modulators for neurological diseases.

Accardi also became the CEO and Co-Founder of Orexia Therapeutics in the same year, which was later acquired by Centessa Pharmaceuticals.

In 2019, they also served as a Non Executive Director at Embody Orthopaedic.

At present, Accardi is the President of the Orexin Program at Centessa Pharmaceuticals, where they are involved in the development of orexin agonists for neurological diseases.

Overall, Mario Alberto Accardi has a diverse and extensive background in the biotechnology and pharmaceutical sectors, with experience in executive roles, board memberships, and venture capital investments.

Mario Alberto Accardi received their International Baccalaureate degree from St George's British International School, Rome, in 2004. Mario Alberto then pursued a Masters degree in Mechanical Engineering from Imperial College London from 2004 to 2008. Subsequently, Mario completed their Ph.D. in Biomedical/Medical Engineering at Imperial College London from 2008 to 2012. Mario Alberto further expanded their knowledge by completing a Postgraduate degree in Genomic Medicine at Imperial College London from 2016 to 2017.